Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-03-11 3:34 pm Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | EcoR1 Capital LLC | 4,155,375 5.3% | 4,155,375 (New Position) | View |
| 2024-03-01 8:05 pm Sale | 13D | Crinetics Pharmaceuticals Inc. CRNX | PERCEPTIVE ADVISORS LLC | 1,488,703 1.9% | -3,844,829 (-72.09%) | View |
| 2024-02-14 6:36 pm Sale | 13G | Crinetics Pharmaceuticals Inc. CRNX | ORBIMED ADVISORS LLC | 1,667,360 2.5% | -1,529,516 (-47.84%) | View |
| 2024-02-14 4:14 pm Sale | 13G | Crinetics Pharmaceuticals Inc. CRNX | Point72 Asset Management L.P. | 3,416,900 5.1% | -311,052 (-8.34%) | View |
| 2024-02-14 4:06 pm Sale | 13G | Crinetics Pharmaceuticals Inc. CRNX | BRAIDWELL LP | 0 0% | -3,469,674 (Position Closed) | View |
| 2024-02-14 10:11 am Sale | 13G | Crinetics Pharmaceuticals Inc. CRNX | BIOTECHNOLOGY VALUE FUND L P | 0 0% | -2,736,613 (Position Closed) | View |
| 2024-02-14 07:54 am Sale | 13G | Crinetics Pharmaceuticals Inc. CRNX | Driehaus Capital Management LLC | 5,039,477 7.54% | -585,267 (-10.41%) | View |
| 2024-02-13 5:02 pm Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | VANGUARD GROUP INC | 3,502,452 5.24% | 3,502,452 (New Position) | View |
| 2024-02-09 08:50 am Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | FMR LLC | 4,043,865 6.053% | 2,160,747 (+114.74%) | View |
| 2024-02-08 10:11 am Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | WELLINGTON MANAGEMENT GROUP LLP | 3,245,105 4.86% | 440,620 (+15.71%) | View |
| 2024-01-25 4:59 pm Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | BlackRock Inc. BLK | 5,345,114 8% | 1,427,625 (+36.44%) | View |
| 2024-01-24 10:28 am Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | STATE STREET CORP STT | 3,563,736 5.34% | 3,563,736 (New Position) | View |
| 2023-09-18 4:24 pm Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | Point72 Asset Management L.P. | 3,727,952 5.6% | 3,727,952 (New Position) | View |
| 2023-02-14 4:12 pm Unchanged | 13G | Crinetics Pharmaceuticals Inc. CRNX | ORBIMED ADVISORS LLC | 3,196,876 5.9% | 0 (Unchanged) | View |
| 2023-02-14 4:06 pm Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | BRAIDWELL LP | 3,469,674 6.45% | 3,469,674 (New Position) | View |
| 2023-02-14 11:58 am Sale | 13G | Crinetics Pharmaceuticals Inc. CRNX | BIOTECHNOLOGY VALUE FUND L P | 2,736,613 5.1% | -267,266 (-8.90%) | View |
| 2023-02-09 09:59 am Sale | 13G | Crinetics Pharmaceuticals Inc. CRNX | FMR LLC | 1,883,118 3.499% | -1,839,176 (-49.41%) | View |
| 2023-02-08 11:32 am Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | Driehaus Capital Management LLC | 5,624,744 10.45% | 831,106 (+17.34%) | View |
| 2023-02-06 2:51 pm Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | WELLINGTON MANAGEMENT GROUP LLP | 2,804,485 5.21% | 2,804,485 (New Position) | View |
| 2023-01-31 1:58 pm Purchase | 13G | Crinetics Pharmaceuticals Inc. CRNX | BlackRock Inc. BLK | 3,917,489 7.3% | 641,319 (+19.58%) | View |